DNLI — Denali Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.20bn
- $1.16bn
- $330.53m
- 56
- 25
- 49
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 26.7 | 336 | 48.7 | 108 | 331 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 240 | 273 | 344 | 449 | 527 |
Operating Profit | -213 | 62.7 | -296 | -341 | -197 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -198 | 72 | -291 | -326 | -145 |
Provision for Income Taxes | |||||
Net Income After Taxes | -198 | 71.1 | -291 | -326 | -145 |
Net Income Before Extraordinary Items | |||||
Net Income | -198 | 71.1 | -291 | -326 | -145 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -198 | 71.1 | -291 | -326 | -145 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.07 | 0.631 | -2.39 | -2.6 | -1.06 |